Last reviewed · How we verify
Sunpg 1622 (TILDRAKIZUMAB)
Sunpg 1622 (generic name: TILDRAKIZUMAB) is a Interleukin-23 Antagonist [EPC] Monoclonal antibody drug developed by Sun Pharma Global. It is currently FDA-approved (first approved 2018) for Moderate-to-severe plaque psoriasis.
Tildrakizumab blocks the action of Interleukin-23, a protein that promotes inflammation.
Sunpg 1622 is an interleukin-23 inhibitor, classified as an antibody drug. It is also known by the synonyms ILUMETRI, Ilumya, MK-3222, SCH-900222, TILDRAKIZUMAB, and TILDRAKIZUMAB.
At a glance
| Generic name | TILDRAKIZUMAB |
|---|---|
| Sponsor | Sun Pharma Global |
| Drug class | Interleukin-23 Antagonist [EPC] |
| Target | Interleukin-23 |
| Modality | Monoclonal antibody |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
| First approval | 2018 |
| Annual revenue | 500 |
Mechanism of action
Tildrakizumab is humanized IgG1/k monoclonal antibody that selectively binds to the p19 subunit of IL-23 and inhibits its interaction with the IL-23 receptor. IL-23 is naturally occurring cytokine that is involved in inflammatory and immune responses. Tildrakizumab inhibits the release of proinflammatory cytokines and chemokines.
Approved indications
- Moderate-to-severe plaque psoriasis
Common side effects
- Upper respiratory infections
- Injection site reactions
- Diarrhea
- Angioedema
- Urticaria
- Dizziness
- Pain in extremity
- Hypersensitivity reactions
Key clinical trials
- A Study to Evaluate the Efficacy and Safety of Subcutaneous Tildrakizumab in Subjects With Moderate to Severe Genital Psoriasis. (PHASE3)
- A Study of Tildrakizumab in Pediatric Subjects With Chronic Plaque Psoriasis (PHASE2,PHASE3)
- Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis (PHASE4)
- Efficacy and Safety of Tildrakizumab Compared to Placebo in Anti-TNF naïve Subjects With Active Psoriatic Arthritis II (INSPIRE 2) (PHASE3)
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis (PHASE3)
- Observational Study of Tildrakizumab in Patients With Moderate to Severe Plaque Psoriasis in Routine Clinical Practice
- Impact of Tildrakizumab on Patient Reported Outcomes in Patients With Moderate-to-severe Psoriasis in Canada
- Safety Study for Prospective Assessment of Pregnancy Outcomes in Patients Treated With Tildrakizumab
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| SEC EDGAR | Revenue + earnings |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Sunpg 1622 CI brief — competitive landscape report
- Sunpg 1622 updates RSS · CI watch RSS
- Sun Pharma Global portfolio CI
Frequently asked questions about Sunpg 1622
What is Sunpg 1622?
How does Sunpg 1622 work?
What is Sunpg 1622 used for?
Who makes Sunpg 1622?
What is the generic name of Sunpg 1622?
What drug class is Sunpg 1622 in?
When was Sunpg 1622 approved?
What development phase is Sunpg 1622 in?
What are the side effects of Sunpg 1622?
What is Sunpg 1622's annual revenue?
What does Sunpg 1622 target?
Related
- Drug class: All Interleukin-23 Antagonist [EPC] drugs
- Target: All drugs targeting Interleukin-23
- Manufacturer: Sun Pharma Global — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Moderate-to-severe plaque psoriasis
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing